These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7088206)

  • 61. New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report.
    Gasbarrini G; Malfertheiner P; Deltenre M; Mégraud F; O'Morain C; Pajares-García J; Quina M; Bianchi Porro G; Gasbarrini A; Franceschi F; Armuzzi A; Cammarota G; Anti M; Pretolani S
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S244-7. PubMed ID: 10077746
    [No Abstract]   [Full Text] [Related]  

  • 62. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
    Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
    Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
    Orziev ZM; Nurbaev FE; Rakhimova GSh
    Klin Med (Mosk); 2003; 81(6):48-9. PubMed ID: 12875192
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Management of Helicobacter pylori-positive peptic ulcer disease.
    Malfertheiner P
    Scand J Gastroenterol Suppl; 1996; 215():69. PubMed ID: 8722386
    [No Abstract]   [Full Text] [Related]  

  • 65. Evaluation of a new bismuth-free triple therapy in nude mice and humans.
    Karita M; Tsuda M; Okita K; Sugiyama T; Nakazawa T
    Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S31-4. PubMed ID: 8574732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
    Peura DA; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1137-9. PubMed ID: 8053422
    [No Abstract]   [Full Text] [Related]  

  • 67. [Long-term therapy of peptic ulcer disease].
    Müller P; Dammann HG; Simon B
    MMW Munch Med Wochenschr; 1982 Nov; 124(44):971-2. PubMed ID: 6296668
    [No Abstract]   [Full Text] [Related]  

  • 68. [Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing].
    Quintero M; Moderos I; Buesa F; Gonzalez Cansino R; Haedo W
    G E N; 1995; 49(2):116-22. PubMed ID: 8566682
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth.
    al-Assi MT; Genta RM; Karttunen TJ; Cole RA; Graham DY
    Am J Gastroenterol; 1995 Mar; 90(3):403-5. PubMed ID: 7872278
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Peptic ulcer and Helicobacter pylori. Comments on the authors' cases].
    Dallera F; Gendarini A; Scanzi G
    Recenti Prog Med; 1993 Jan; 84(1):34-7. PubMed ID: 8430247
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Therapy of peptic ulcer with cytoprotective substances].
    Fortunat W
    Wien Med Wochenschr; 1983; 133(4-5):94-8. PubMed ID: 6407215
    [No Abstract]   [Full Text] [Related]  

  • 72. Role of protective drugs in the prevention of ulcer relapse.
    Ota S; Terano A
    J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gastroprotection by antisecretory and non-antisecretory agents.
    Konturek SJ
    Klin Wochenschr; 1986; 64 Suppl 7():24-7. PubMed ID: 3560779
    [No Abstract]   [Full Text] [Related]  

  • 74. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
    al-Assi MT; Ramirez FC; Lew GM; Genta RM; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1203-5. PubMed ID: 8053435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients--a preliminary report.
    Papp J; Juhasz L; Lakatos L; Lonovits J; Szekely I; Tarnok F; Tulassay Z; Varkonyi T
    Br J Clin Pract; 1996; 50(5):249-53. PubMed ID: 8794601
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bismuth subcitrate nephrotoxicity. A reversible cause of acute oliguric renal failure.
    Sarikaya M; Sevinc A; Ulu R; Ates F; Ari F
    Nephron; 2002 Apr; 90(4):501-2. PubMed ID: 11961412
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Modern drugs used in the treatment of peptic ulcer].
    Ignat'ev MV
    Med Sestra; 1988 May; 47(5):41-6. PubMed ID: 3412153
    [No Abstract]   [Full Text] [Related]  

  • 79. [Long-term therapy of peptic ulcer].
    Berndt H
    Z Arztl Fortbild (Jena); 1992 Mar; 86(6):287-90. PubMed ID: 1590008
    [No Abstract]   [Full Text] [Related]  

  • 80. Acute renal failure after overdose of colloidal bismuth subcitrate.
    Cengiz N; Uslu Y; Gök F; Anarat A
    Pediatr Nephrol; 2005 Sep; 20(9):1355-8. PubMed ID: 15947979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.